Global Cancer Stem Cells Market Assessment, By Mode of Action [Targeted Cancerous Stem Cells (CSCs), Stem Cell Usage Against Cancer], By Cancer Forms [Breast, Blood, Lung, Prostate, Others], By Region, Opportunities and Forecast, 2018-2032F

Global cancer stem cells market is projected to witness a CAGR of 10.29% during the forecast period 2025-2032, growing from USD 2.49 billion in 2024 to USD 5.46 billion in 2032. The rising incidence of cancer, increased research and development (R&D), and growing use of stem cells are primarily contributing to the market. The global cancer stem cell (CSC) market is experiencing substantial expansion due to the rising global cancer rates. At the same time, medical science pursues root-cause therapies for tumors that lead to metastasis and recurrence.

Report Attribute	Details
Base Year	2024
Forecast Period	2025-2032F
Historical Period	2018-2023
Projected Growth Rate	CAGR of 10.29% between 2024 and 2032
Revenue Forecast in 2032	USD 5.46 billion

Tumor cells known as CSCs possess both self-renewal capabilities and the ability to start and maintain tumor development. Conventional cancer treatments fail to eliminate these cells effectively; thus, doctors observe disease relapses along with unfavorable long-term results in their patients. Medical research now focuses on developing therapies that target the elimination of these specific cells. The market experiences significant growth due to rapid technological advancements in cellular biology, genomic research, and precision medicine approaches. The development of single-cell sequencing technology, together with 3D tumor models and CRISPR gene editing, enables scientists to discover CSCs along with their isolation and analysis, which speeds up the production of targeted treatments. Biotech firms, along with academic institutions, collaborate on CSC research, while regulatory agencies expedite drug approval for CSC-targeted therapies. North America dominates the market due to its prominent research infrastructure, high healthcare spending, and high cancer incidence rates. In contrast, the Asia-Pacific region is emerging as the fastest-growing area, driven by improved healthcare systems and increasing capital expenditure on cancer research. The CSC market will continue to grow steadily despite facing some significant challenges (as high development costs, regulatory hurdles, and technical factors preventing the isolation of pure conglomerates of CSCs). However, with an increased global focus on personalized and long-lasting cancer treatment approaches and innovative therapies, it is an encouraging time to be a part of the potential CSC market.

For instance, according to the American Cancer Society, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States in 2025. demand for the stem cell market.

Investment in Research and Development Boosts Market Demand

Investment in research and development is significantly fueling the growth in the cancer stem cell (CSC) market. A considerable number of R&D projects are currently focused on understanding CSC biology, primarily because significant R&D efforts focus on understanding CSC biology, which drives tumor recurrence and metastasis and causes resistance to standard treatments. Research institutions, together with pharmaceutical and biotechnology organizations, invest heavily in single-cell analysis, gene editing, and 3D tumor modeling platforms to discover and confirm CSC-specific targets. The current advancements enable faster discoveries of new therapeutic agents and companion diagnostics, which provide better elimination of CSCs, leading to better long-term treatment results. Increased public and private funding, together with government grants and worldwide partnerships, help fund preclinical and clinical development programs. The impending commercialization of innovative solutions expands therapeutic options while increasing investor trust, which in turn drives worldwide market demand for CSC-focused solutions.

For instance, in July 2024, after a USD 3 million investment by Dr. Ronald Rigor, Calidi Biotherapeutics Inc., launched its subsidiary Nova Cell to progress further Adult Adipose Allogeneic (AAA) stem cell programs for regenerative medicine. Additionally, Dr. Rigor has accepted a position on Calidi's advisory board. Beginning in 2025, Dr. Rigor developed Adult Adipose Allogeneic stem cells in the Philippines.

Scientific and Technological Advances Fuel Market Growth

 Advancements in science and technology significantly impact the global cancer stem cell (CSC) market by enhancing the ability to identify, study, and target CSCs, which contribute to the initiation of tumors, metastasis, and resistance to therapy. The medical field now benefits from single-cell sequencing, together with CRISPR gene editing and 3D organoid tumor models, which provide advanced knowledge about CSC biology and behavior. The research tools enable scientists to trace CSC molecular profiles while investigating resistance mechanisms and create targeted therapies that focus on specific pathways, including Wnt, Notch, and Hedgehog. Doctors now utilize nanoparticles in conjunction with liposomes and antibody-drug conjugates as enhanced drug delivery systems to improve the accuracy and effectiveness of CSC-targeted therapies. Recent technological breakthroughs have decreased product development durations while delivering better results, attracting significant investments from biotechnology companies and research organizations. As the demand for more effective, long-term treatments for cancers increases, scientific innovation will continue to fuel the global expansion of the CSC market and market form.

For instance, in September 2024, Mobilization Matters, a vital digital resource for individuals with multiple myeloma who are about to undergo stem cell collection for an autologous stem cell transplant, was launched by BioLineRx Ltd., a commercial-stage biopharmaceutical company focused on developing life-changing treatments in oncology and rare diseases.

Breast Cancer Form Hold the Largest Market Share

Breast cancer has the largest share of the global cancer stem cell (CSC) market, as it has a high incidence, and the association of cancer stem cells with tumorigenesis in breast cancer. Typically, breast cancer stem cells (BCSCs) have been investigated as a population of cells phenotyped using various differentiation markers, such as CD44+/CD24−/low and ALDH1+, and their use as a clinical marker has been developed and validated in preclinical and clinical studies. They are contributing factors in resistance to therapy, metastasis, and recurrence; as such, they are targets for novel therapeutics. There has been a significant increase in the burden of breast cancer in developed countries, such as the United States, Canada, Germany, and the UK, and thus increased funding for interventions targeting BCSCs. Sequenced advances in organoid models, utilizing 3D culture conditions, single-cell sequencing, and more sophisticated drug delivery systems, have enabled the better detection of BCSCs and drug screening efforts targeting these cells. To accelerate clinical trials, an increase in partnerships and collaboration is being fostered between academic and pharmaceutical industries, focused exclusively on exploratory clinical trials of therapies targeting CSCs for breast cancer. For these reasons, breast cancer will continue to have the largest market share in the cancer stem cell marketplace.

For instance, in December 2024, Eterna Therapeutics Inc. announced a collaboration with MD Anderson Cancer Center to evaluate the company's lead induced mesenchymal stem cell therapy candidate, ERNA-101, for its potential use in inducing and modulating antitumor immunity in ovarian and breast cancer models, aiming to advance treatments for solid tumors.

North America Dominates Cancer Stem Cells Market

North America dominates the global cancer stem cells (CSC) market due to its state-of-the-art healthcare systems, substantial funding for cancer research, and the presence of significant biotechnology and pharmaceutical companies. Cancer types such as breast, lung, and colorectal are highly prevalent in this region, likely due to the excellent relationship of these cancers associated with recurrence and drug-resistance driven by CSc. The U.S. is the regional leader in part because of its significant government channels to support stem cell-based oncology research and clinical trials; a strong engagement with the National Cancer Institute (NCI) and the National Institutes of Health (NIH) is likely a contributing factor. The U.S. is at the global forefront of adopting emerging technologies, such as CRISPR, Next-Generation approaches in single-cell genomics, and 3D tumor models, to accelerate the discovery of CSc and the development of specific therapies. The North American region maintains this market position through strong academic institutions, industry partnerships, key players in the area, and a streamlined regulatory pathway for rapid approvals. The market growth receives support from rising awareness levels, along with early cancer screening initiatives and numerous cancer research centers in the region. These combined factors establish North America as the largest and most advanced region for cancer stem cells, which serves as the global benchmark for innovation and commercialization.

For instance, in October 2024, 11 early-career researchers and research teams were awarded funding from the Biden Cancer Moonshot because of their innovative proposals to diagnose, treat, and prevent cancer. One of the President’s Unity Agenda priorities is to expedite the fight against cancer. Through the National Cancer Institute and as part of the Cancer Moonshot Scholars program, the Biden-Harris Administration is allocating over USD 6 million in the second cohort of this program. Such investment helps this region to grow fast in the cancer stem cells market.

Download Free Sample Report

Impact of U.S. Tariffs on Global Cancer Stem Cells Market

The implementation of United States tariffs on medical equipment, laboratory apparatus, and raw materials has significantly affected the cancer stem cell (CSC) market. The tariffs have increased the prices of critical research tools, including cell culture media, reagents, and specialized equipment that researchers obtain from foreign suppliers. Several biotechnology companies and research institutions experience increased operational costs, which may reduce their ongoing and future CSC-related research activities. The business operations of smaller companies face greater risks due to their limited financial resources and narrow profit margins. Several organizations have started transferring their research and development work to countries that maintain lower trade restrictions. The procurement process and search for new suppliers extend project schedules, which also contributes to delays. The immediate obstacles created by these issues may lead to increased domestic production of essential research materials, which will strengthen supply chains and enhance U.S. CSC research independence.

Report Scope

“Global Cancer Stem Cells Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global cancer stem cells market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecasts between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Mode of Action, Cancer Forms
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profiled	Thermo Fisher Scientific, Inc., AbbVie, Inc., Lonza Group Ltd., The Menarini Group, Miltenyi Biotec B.V. & Co. KG, PromoCell GmbH, MacroGenics, Inc., STEMCELL Technologies Canada Inc., Sino Biological, Inc., Lineage Cell Therapeutics, Inc.
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, the global cancer stem cells market has been segmented into the following categories: 

• By Mode of Action
  • Targeted Cancerous Stem Cells (CSCs)
  • Stem Cell Usage Against Cancer
• By Cancer Forms
  • Breast
  • Blood
  • Lung
  • Prostate
  • Others
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Players Landscape and Outlook

The cancer stem cell market competition framework is one that is characterized by innovation, alliances, and significant research and development expenditure. Major players are focused on developing targeted therapies while utilizing innovations such as CRISPR, 3D culture systems, and single-cell sequencing approaches to narrow down the specificity of successor drug molecules. Additionally, integration with academic institutions and biotechnological companies contributes to clinical development, thereby advancing product pipelines. New companies and established firms alike want to broaden their geographical footprint and invest in life-cycle cost reduction strategies (such as personalized medicine) to help fulfill unmet needs in cancer treatment. As there is an increasing demand for effective and safe therapeutics with long-lasting effects, the overall outlook for the cancer stem cell market remains positive, driven by regulatory incentives and growing interest in all corners of the world towards CSC-targeted oncology solutions.

In June 2025, STEMCELL Technologies Canada Inc. acquired Cellular Highways Ltd. early in 2025 and now has access to the Highway1 instrument with VACS technology for gentle, high-speed cell sorting. This is particularly suited for sensitive cell populations, such as cancer stem cells, thereby improving workflows in research and therapeutic development.

Key Players Operating in Global Cancer Stem Cells Market are:

• Thermo Fisher Scientific, Inc.
• AbbVie, Inc.
• Lonza Group Ltd.
• The Menarini Group
• Miltenyi Biotec B.V. & Co. KG
• PromoCell GmbH
• MacroGenics, Inc.
• STEMCELL Technologies Canada Inc.
• Sino Biological, Inc.
• Lineage Cell Therapeutics, Inc.

If you can't find what you're searching for or have any custom requirements for global cancer stem cells market, you may approach our team at info@marketsandata.com.